Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Endocrine 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9lutetium Lu 177 dotatate 6cabozantinib 6Nivolumab 5Ipilimumab 4fludarabine 3X-Rays 3Phantoms, Imaging 3Etoposide 3Cyclophosphamide 3CTLA-4 Antigen 3pembrolizumab 2olaparib 2aldesleukin 2Lutetium-177 2Lutetium 2Irinotecan 2Cisplatin 2Carboplatin 2trametinib 1tivozanib 1tipifarnib 1selpercatinib 1repotrectinib 1pazopanib 1gallium Ga 68 dotatate 1gallium 68 PSMA-11 1fluorodopa F 18 1fluorocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
IFL protocol × Endocrine × 30 days × Clear all
NCT07595913 2026-05-19

A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Not yet recruiting
240 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡